Neuropsychopharmacology Reports最新文献

{"title":"Memantine as an Adjunctive Treatment for Residual Anxiety and Agitation in Early Parkinson's Disease With Depression: A Case Report.","authors":"Takaumi Haga, Yuhei Mori, Nozomu Matsuda, Aya Sato, Yuhei Suzuki, Jiro Ono, Itaru Miura","doi":"10.1002/npr2.70129","DOIUrl":"10.1002/npr2.70129","url":null,"abstract":"<p><strong>Background: </strong>Non-motor psychiatric symptoms, including anxiety, agitation, and irritability, are common in Parkinson's disease (PD) and may persist despite antidepressant treatment. While monoaminergic dysfunction has traditionally been emphasized, accumulating evidence suggests that glutamatergic dysregulation, particularly involving N-methyl-D-aspartate (NMDA) receptors, may contribute to these symptoms. However, clinical evidence supporting NMDA receptor modulation in early-stage PD without dementia remains limited.</p><p><strong>Case presentation: </strong>We report the case of a 65-year-old woman with early-stage PD (Hoehn and Yahr stage I) who developed a severe depressive episode accompanied by prominent anxiety and agitation. Treatment with vortioxetine resulted in partial improvement of depressive symptoms, as reflected by a gradual reduction in the Montgomery-Åsberg Depression Rating Scale score; however, significant anxiety, agitation, and irritability persisted despite adjunctive brexpiprazole, necessitating behavioral restriction. Given the limited response and the clinical characteristics of the residual symptoms, low-dose memantine (5 mg/day) was introduced as an off-label adjunctive therapy after obtaining informed consent. Approximately 10 days after memantine initiation, anxiety and agitation markedly improved, allowing discontinuation of behavioral restriction. Motor symptoms and cognitive function remained stable throughout treatment and follow-up.</p><p><strong>Conclusion: </strong>This case suggests that NMDA receptor antagonism with low-dose memantine may be a well-tolerated adjunctive option for residual anxiety and agitation in early-stage PD without dementia when conventional antidepressant treatment is insufficient. Although interpretation is limited by the single-case design and concomitant medications, the findings support further investigation of glutamatergic mechanisms and NMDA receptor modulation in the management of non-motor psychiatric symptoms in PD.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70129"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147932027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Alcohol Drinking Patterns and Multiple Metabolic Syndrome Components in Non-Obese and Obese Individuals.","authors":"Ayako Kikuchi, Hisashi Yoshimoto, Takafumi Monma, Sakiko Ozawa, Momoko Tsuchida, Fumi Takeda","doi":"10.1002/npr2.70105","DOIUrl":"10.1002/npr2.70105","url":null,"abstract":"<p><strong>Aim: </strong>This cross-sectional study aimed to investigate the relationship between drinking patterns (combination of the frequency and amount of alcohol consumption) and the possession of multiple metabolic syndrome (MetS) components in non-obese and obese individuals.</p><p><strong>Methods: </strong>Data derived from medical examinations, specific health checkup questionnaires, and health insurance claims of 36 006 individuals aged 40-64 years from five health insurance associations affiliated with Japanese companies were analyzed. Modified Poisson regression analysis was conducted with multiple MetS components as the objective variable, drinking patterns as the explanatory variable, and sex, age, weight gain ≥ 10 kg since the age of 20 years, and lifestyle habits except for drinking patterns as adjustment variables.</p><p><strong>Results: </strong>Drinking patterns associated with a high risk of possessing multiple MetS components were \"everyday drinking\" ≥ 20 g/day and \"sometimes drinking\" ≥ 40 g/day in non-obese individuals and \"everyday drinking\" ≥ 60 g/day in obese individuals. Across these risky drinking patterns, the prevalence ratios for the possession of multiple MetS components were higher in non-obese individuals than in obese individuals. Conversely, drinking patterns associated with a lower risk of possessing multiple MetS components were \"everyday drinking < 20 g/day\" in non-obese individuals and \"sometimes drinking < 20 g/day\" and \"everyday drinking < 20 g/day\" in obese individuals.</p><p><strong>Conclusion: </strong>Non-obese individuals, even when drinking less frequently and in smaller amounts, showed a higher risk of possessing multiple MetS components than obese individuals, underscoring the importance of supporting reduced alcohol consumption among non-obese individuals.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70105"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13283923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcranial Calcium Macro-Imaging From the Auditory Cortex of Thy1-Cre-Driven GCaMP8 Transgenic Rats.","authors":"Manavu Tohmi, Hisaaki Namba, Meiko Kawamura, Ryuichi Hishida, Shota Iguchi, Kazuto Kobayashi, Natsuki Matsushita, Tomoji Mashimo, Rie Natsume, Kenji Sakimura, Hiroyuki Nawa","doi":"10.1002/npr2.70113","DOIUrl":"10.1002/npr2.70113","url":null,"abstract":"<p><strong>Background: </strong>Genetically encoded calcium indicators such as GCaMP enable us to monitor neuronal activities from living animals at synaptic levels as well as at whole-brain levels. However, the genetic variation of GCaMP transgenic rats is limited compared with the various demands for neuroscience studies on rats.</p><p><strong>Method: </strong>We established two transgenic rat lines: one expressing Cre recombinase under the control of the Thy1 promoter and another knock-in line carrying a floxed STOP cassette followed by GCaMP8 inserted into the β-actin locus. We mated these two transgenic rats and produced the Thy1-Cre-driven GCaMP8-expressing rats.</p><p><strong>Results: </strong>Approximately 80% of cortical neurons were positive for the GCaMP immunoreactivity. The GCaMP8-expressing rats were subjected to transcranial calcium imaging from the auditory cortex under anesthesia. With this simple procedure, we were able to detect the maximum responses to 68 dB click sounds;ΔF/F₀ = 1.2%. The rise time reaching the peak response was approximately 150 ms, and the half decay time was about 150 ms.</p><p><strong>Conclusions: </strong>These results suggest that the present GCaMP8-expressing rats as well as their parental transgenic rat strains offer a new tool for cortical macro-imaging and functional mapping with the transcranial approach.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70113"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147776396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Versus Monotherapy in Acute Anti-LGI1 Encephalitis: A Real-World Dose Optimization Analysis.","authors":"Yao Tan, Ming Sun, Qinqin Liu, Beibei Huang, Chao Wu, Jie Lu, Donglin Zhu","doi":"10.1002/npr2.70112","DOIUrl":"10.1002/npr2.70112","url":null,"abstract":"<p><strong>Background: </strong>Anti-leucine-rich-glioma-inactivated 1 encephalitis (LGI1e) predominantly affects older adults, who frequently present with chronic comorbidities. Given their heightened susceptibility to adverse effects, optimizing immunotherapy is critical for this high-risk population. Therefore, this study compared the efficacy and safety of intravenous immunoglobulin (IVIg), intravenous methylprednisolone (IVMP) at 500 or 1000 mg/day, and combined IVIg with IVMP to define an optimal efficacy-safety balanced regimen for LGI1e.</p><p><strong>Methods: </strong>A total of 131 LGI1e patients were comprehensively analyzed. The efficacy was assessed through the therapeutic response rate, response latency, and the improvement in the Clinical Assessment Scale for Autoimmune Encephalitis (CASE), the modified Rankin Scale (mRS), the Mini-Mental State Examination (MMSE), and faciobrachial dystonic seizure (FBDS), while safety was evaluated by analyzing the incidence and severity of adverse events (AEs).</p><p><strong>Results: </strong>Compared with IVIg or IVMP monotherapy, the IVIg+IVMP combination achieved higher response rates, shorter latency, and greater improvements in CASE, mRS, and FBDS. While 1000 mg IVMP reduced response latency and FBDS cessation time versus 500 mg, both doses showed comparable response rates. IVMP-containing regimens increased AEs, especially at 1000 mg. Diabetes was the sole independent AE risk factor during acute immunotherapies. Initial regimens had no long-term outcome association, and cognitive impairment persisted as a major disability contributor.</p><p><strong>Conclusion: </strong>For LGI1e patients, combined IVIg and corticosteroid demonstrate superior efficacy to monotherapy as first-line treatment, with a starting IVMP dose of 500 mg (vs. 1000 mg) considered optimal. Furthermore, post-immunotherapy cognitive impairment requires sustained management. These findings necessitate validation in larger randomized trials.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70112"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japanese Cohort Study and Meta-Analysis Demonstrate Significant Association Between Serotonin Transporter-Linked Polymorphic Region and Schizophrenia.","authors":"Masao Miyachi, Toshiyuki Shirai, Shohei Okada, Kiriko Minami, Ryo Tsukamoto, Kentaro Mouri, Satoshi Okazaki, Ikuo Otsuka, Akitoyo Hishimoto","doi":"10.1002/npr2.70114","DOIUrl":"10.1002/npr2.70114","url":null,"abstract":"<p><p>Schizophrenia is a prevalent psychiatric disease that substantially affects health and increases mortality risk. The 5-hydroxytryptamine system has been implicated in its pathogenesis. The SLC6A4 gene encodes the serotonin transporter, which regulates synaptic 5-hydroxytryptamine through reuptake into presynaptic neurons. Within its promoter region, there is a 44-base pair insertion/deletion polymorphism, known as serotonin-transporter-linked polymorphic region (5-HTTLPR). We investigated the association between 5-HTTLPR polymorphism and schizophrenia in the cohorts, including the largest sample size of Asian schizophrenia patients to date. We included 467 patients with schizophrenia and 361 controls, all of Japanese ancestry. We extracted DNA from peripheral blood samples. After amplification with PCR, we analyzed the association between 5-HTTLPR genotypes and alleles and schizophrenia. Furthermore, we conducted a meta-analysis with previous literatures. 5-HTTLPR genotype distribution differed significantly between patients and controls (p = 0.007). The short allele was significantly more frequent in schizophrenia patients (odds ratio = 1.39 [95% Cl = 1.08-1.77], p = 0.007). The meta-analysis demonstrated a significant association between the short allele and schizophrenia (odds ratio = 1.06 [95% Cl = 1.01-1.11], p = 0.024). This study demonstrates a significant association between 5-HTTLPR polymorphism and schizophrenia. While further research is needed, the findings suggest 5-HTTLPR may represent a promising target for future therapeutic strategies.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70114"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clopidogrel, an ADP-P2Y12 Receptor Antagonist, Is Associated With Lower Opioid Consumption and a Reduced Incidence of Delirium in Cancer Patients Receiving Chemotherapy: A Nationwide Retrospective Cohort Study in Japan.","authors":"Hiroaki Abe, Reo Inoue, Takamichi Kogure, Rikuhei Tsuchida, Hiroaki Owada, Yoshika Sudo, Yaeko Yokoshima, Hiroki Matsui, Hideo Yasunaga, Masahiko Sumitani","doi":"10.1002/npr2.70142","DOIUrl":"10.1002/npr2.70142","url":null,"abstract":"<p><strong>Background: </strong>P2Y12 receptor activation stimulates spinal microglia and exacerbates pain. However, whether clopidogrel, a P2Y12 receptor antagonist, has analgesic properties remains unclear. This study aimed to evaluate the association between clopidogrel use and opioid consumption in cancer patients receiving chemotherapy.</p><p><strong>Methods: </strong>We identified cancer patients receiving inpatient chemotherapy between January 2019 and December 2020 using the Diagnosis Procedure Combination database, a Japanese national inpatient database. Propensity score matching was conducted between clopidogrel and aspirin users. The primary outcome was opioid consumption during hospitalization. The secondary outcomes included analgesic use (opioids, acetaminophen, nonsteroidal anti-inflammatory drugs, and gabapentinoids) and hyperactive delirium.</p><p><strong>Results: </strong>Among 71 554 eligible patients (male, 73%; mean age, 73.7 years), 25.3% were administered clopidogrel and 74.7% were administered aspirin. Propensity score matching included 18 135 and 36 270 patients in the clopidogrel and aspirin groups, respectively. The median daily opioid consumption in morphine milligram equivalent was significantly lower in the clopidogrel group than in the aspirin group (16.4 mg/day vs. 21.4 mg/day; p < 0.001). The analgesic use was significantly lower in the clopidogrel group for opioids (odds ratio [OR], 0.83; 95% confidence interval [CI], 0.78-0.88; p < 0.001), acetaminophen (OR, 0.91; 95% CI, 0.88-0.95; p < 0.001), and nonsteroidal anti-inflammatory drugs (OR, 0.83; 95% CI, 0.80-0.87; p < 0.001). Moreover, the occurrence of hyperactive delirium was significantly lower in the clopidogrel group (OR, 0.80; 95% CI, 0.69-0.92; p = 0.002).</p><p><strong>Conclusions: </strong>Clopidogrel may have an analgesic effect in cancer patients receiving chemotherapy.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70142"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13265146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148252608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between Serum Adipokine, Antipsychotic Exposure, and Clinical Characteristics in Chronic Schizophrenia: A Cross-Sectional Study.","authors":"Yasuhiro Ohno, Kiyomi Saito, Keita Hanabusa, Ayaka Nakai, Tomoko Nagai, Noriko Hida, Kenji Sanada","doi":"10.1002/npr2.70123","DOIUrl":"10.1002/npr2.70123","url":null,"abstract":"<p><strong>Background: </strong>Previous meta-analyses have reported lower serum adiponectin levels in patients with schizophrenia treated with second-generation antipsychotics. However, the relationships among serum adipokines, psychiatric symptoms, and antipsychotic use remain unclear. This study aimed to clarify associations between serum adipokines, psychiatric symptoms, and antipsychotic treatment in patients with chronic schizophrenia compared with healthy controls.</p><p><strong>Methods: </strong>The study included 37 inpatients with schizophrenia and 39 age- and gender-matched healthy controls. Fasting blood samples were collected, and serum adipokine levels were measured using enzyme-linked immunosorbent assays. Psychiatric symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS), and antipsychotic doses were converted to chlorpromazine equivalents. Correlations were examined using regression and multivariate analyses, including adjustment for body mass index (BMI).</p><p><strong>Results: </strong>No significant case-control differences were observed in total or high-molecular weight adiponectin levels. Female patients had a significantly higher leptin/adiponectin ratio than female controls (p = 0.041). In the schizophrenia group, adiponectin levels were positively correlated with chlorpromazine equivalents (r = 0.684, p < 0.001). This association remained statistically significant after adjustment for BMI, gender and hospitalization period. Adiponectin levels were not significantly associated with psychiatric symptom severity.</p><p><strong>Conclusion: </strong>In this cross-sectional sample, serum adiponectin levels are associated with antipsychotic dosage but not with symptom severity. These findings suggest that adipokine regulation in patients with schizophrenia may be influenced by treatment-related and demographic factors. Longitudinal studies incorporating comprehensive metabolic assessments are needed to explore the clinical significance of these relationships.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70123"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13100884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Histamine H₃ Receptor Antagonist/Inverse Agonist Pitolisant on Temporal Prediction, Spatial Switching, and Spontaneous Locomotion in Mice.","authors":"Shohei Kaneko, Kazuko Hayashi, Kota Yamada, Koji Toda","doi":"10.1002/npr2.70115","DOIUrl":"10.1002/npr2.70115","url":null,"abstract":"<p><p>Histamine receptors contribute to a wide range of brain functions, including arousal, motivation, attention, and memory, but their causal involvement in switching behavior remains insufficiently understood. Here, we examined the effects of systemic administration of pitolisant, a histamine H₃ receptor antagonist/inverse agonist, on adaptation to environmental changes in male mice using two behavioral experiments: a head-fixed Pavlovian spatial switching temporal conditioning task and a freely-moving open-field assay. In the switching task, mice trained without external sensory cues rapidly adjusted both anticipatory and consummatory licking following a switch in reward location, demonstrating robust switching of temporal prediction to a new reward location. Pitolisant administration did not alter anticipatory licking, consummatory licking, or switching performance, indicating that H₃ receptor blockade does not modulate temporal prediction and switching behavior in this assay. In contrast, high-dose pitolisant markedly reduced spontaneous locomotor activity in the open-field and fecal output, suggesting dose-dependent effects on motor and autonomic function. Together, these findings indicate that histamine H₃ receptor signaling exerts selective behavioral influences, with minimal impact on temporal prediction and spatial switching behavior under the present task conditions but clear effects on physiological and motor domains. This work refines the understanding of histaminergic modulation in complex behavior and highlights important considerations for interpreting the cognitive and noncognitive consequences of H₃ receptor-targeting therapeutics.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70115"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13045490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Difference in Effect of the OPRM1 Gene A118G (rs1799971) Single-Nucleotide Polymorphism on the Requirement for Postoperative Fentanyl in Japanese Patients Who Underwent Laparoscopic-Assisted Colectomy.","authors":"Hideyuki Nakagawa, Daisuke Nishizawa, Tsutomu Mieda, Miki Tsujita, Shinya Kasai, Junko Hasegawa, Kyoko Nakayama, Yuko Ebata, Akira Kitamura, Masakazu Hayashida, Kazutaka Ikeda","doi":"10.1002/npr2.70140","DOIUrl":"10.1002/npr2.70140","url":null,"abstract":"<p><strong>Background: </strong>The A118G (rs1799971) single-nucleotide polymorphism (SNP) of the OPRM1 gene, which encodes the μ-opioid receptor, reportedly affects postoperative morphine requirements but not fentanyl requirements. The present study investigated whether this SNP influences postoperative fentanyl requirements after laparoscopic-assisted colectomy (LAC).</p><p><strong>Methods: </strong>We examined 350 Japanese patients who underwent LAC for colorectal cancer. Postoperative pain was managed with an initial intravenous bolus dose of fentanyl, followed by intravenous fentanyl patient-controlled analgesia (PCA). The primary endpoint was the 12-h postoperative fentanyl requirement, defined as the sum of the initial bolus dose and PCA consumption at 12 h postoperatively, which was normalized to body weight. Genotypes of the A118G SNP were obtained from our previous whole-genome genotyping. Associations between genotypes and pain-related phenotypes were analyzed using the Jonckheere-Terpstra test, followed by the Mann-Whitney U test. Values of p < 0.05 were considered statistically significant.</p><p><strong>Results: </strong>In the total cohort, the 12-h postoperative fentanyl requirement was significantly higher in GG homozygotes than in AA homozygotes (p = 0.022). Among 217 males, it was higher in GG homozygotes than in both AA homozygotes (p = 0.006) and AG heterozygotes (p = 0.038). In contrast, among 133 females, this endpoint was unaffected by the genotype of the A118G SNP.</p><p><strong>Conclusion: </strong>In patients who underwent LAC, the OPRM1 A118G SNP significantly influenced postoperative fentanyl requirements in the total cohort, but this effect was observed only in males. These findings indicate a sex-dependent influence of the A118G SNP on postoperative fentanyl requirements in Japanese patients who underwent LAC.</p><p><strong>Trial registration: </strong>University Hospital Medical Information Network Clinical Trials Registry (Trial ID: UMIN000003814).</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70140"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148157604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Happiness and Attention Deficit/Hyperactivity Disorder Symptoms as Mediated by Subjective Health Conditions: A Nationwide Cross-Sectional Internet Survey.","authors":"Norio Sugawara, Takahiro Tabuchi, Keita Tokumitsu, Norio Yasui-Furukori","doi":"10.1002/npr2.70137","DOIUrl":"10.1002/npr2.70137","url":null,"abstract":"<p><strong>Objectives: </strong>There has been limited examination of happiness among individuals with attention-deficit/hyperactivity disorder (ADHD), despite growing interest in psychiatric comorbidities associated with this disorder. This study aims to fill this gap by exploring the relationship between ADHD symptoms and happiness on the basis of data from the Japan Society and New Tobacco Internet Survey (JASTIS).</p><p><strong>Method: </strong>A nationwide, cross-sectional internet survey was conducted in Japan between January and February 2024. The analytic sample comprised 29 268 individuals aged 16 years and above in Japan. Based on questionnaire responses of the 6-item short version of the Japanese version of the Adult ADHD Self-Report Scale (ASRS-J-6), the respondents were classified as possible ADHD or not. Information on happiness was collected via a single (10-point Likert scale) measure.</p><p><strong>Results: </strong>Multivariable ordinal logistic regression analysis and a mediation analysis were performed to examine associations. Possible ADHD was associated with increased odds of feeling less happy. Very high somatic symptoms (41.1% mediation), confusion/difficulty to concentrate (37.2%), and depression (14.8%) were important mediators of the association between ADHD and happiness.</p><p><strong>Conclusions: </strong>Although the majority of individuals with possible ADHD were classified as having moderate happiness, more than one in four were classified as having low happiness. To increase the happiness of individuals with ADHD, screening and treating for both physical and psychiatric symptoms might be important.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70137"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13240280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148033521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}